These stocks offer high yields, are big names in their respective sectors, and have strong fundamentals.

Pfizer (NYSE:PFE) has been dismissed as a defendant in a major federal lawsuit alleging generic drug price fixing. The court ...

Pfizer Inc gains attention as pipeline expansion, metabolic medicine, oncology progress and regulatory developments keep the ...

It could prove to be a case of better later than never for the healthcare giant.

Pfizer expands its oncology portfolio after EU approval for the Keytruda and Padcev regimen, strengthening its cancer ...

With an annual dividend yield of 6.96%, Pfizer Inc. (NYSE:PFE) is included among the 12 Best S&P 500 Stocks to Buy for ...

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2026 dividend on the company’s common stock, payable September 1, 2026, to holders of the Common ...

Analysts' ratings for Pfizer (NYSE:PFE) over the last quarter vary from bullish to bearish, as provided by 7 analysts. The table below offers a condensed view of their recent ratings, showcasing the ...

Cantor Fitzgerald analyst Carter Gould maintained a Hold rating on Pfizer yesterday and set a price target of $27.00. The company’s shares closed yesterday at $25.08. TipRanks' ...

Pfizer (NYSE: PFE) is one of the world's largest drugmakers. That doesn't guarantee the company's success, but it does provide the company with some important long-term advantages. Currently, however, ...

Everyone is still arguing about Novo Nordisk (NYSE:NVO), the Danish obesity juggernaut whose GLP-1 franchise turned Wegovy ...